Monte Rosa Therapeutics EBIT

Monte Rosa Therapeutics (GLUE) currently reports a EBIT of $-180M as of June 2026. That compares with $13M in the prior-year period — down 1470.7% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore Monte Rosa Therapeutics's EBIT history and peer comparisons.

Monte Rosa Therapeutics's EBIT decreased from $13M to $-180M — a 1470.7% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Monte Rosa Therapeutics's EBIT of $-180M is lower than the Healthcare sector average of $22B. That is roughly 100.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Monte Rosa Therapeutics reported $-180M in EBIT as of June 2026. That compares with $13M in the prior-year period — down 1470.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-180M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for Monte Rosa Therapeutics, and consider following GLUE for alerts when major investors trade the stock.